Publication | Closed Access
Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.
88
Citations
28
References
1993
Year
Neurotoxicity was dose-limiting when Taxol was administered by 24-hour continuous infusion to pediatric patients with relapsed solid tumors. In this population, the recommended dose for phase II trials is 350 mg/m2/d.
| Year | Citations | |
|---|---|---|
Page 1
Page 1